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ABSTRACT The definition of a disease requires that distinguishing signs and symptoms are present that
are common, and that the constellation of signs and symptoms differentiate the condition from other
causes. In bronchiectasis, anatomical changes, airways inflammation and airway infection are the
distinguishing features that are common to this disease. However, bronchiectasis is a heterogenous disease:
signs and symptoms are shared with other airway diseases, there are multiple aetiologies and certain
phenotypes of bronchiectasis have distinct clinical and laboratory features that are not common to all
people with bronchiectasis. Furthermore, response to therapeutic interventions in clinical trials is not
uniform. The concept of bronchiectasis as a treatable trait has been suggested, but this may be too
restrictive in view of the heterogeneity of bronchiectasis. It is our opinion that bronchiectasis should be
defined as a disease in its own right, but one that shares several pathophysiological features and “treatable
traits” with other airway diseases. These traits define the large heterogeneity in the pathogenesis and
clinical features and suggest a more targeted approach to therapy.
Introduction
What is a disease? According to the Merriam–Webster dictionary, the definition of disease is “a condition
of the living animal […] or of one of its parts that impairs normal functioning and is typically manifested
by distinguishing signs and symptoms”. However, what counts as a disease may evolve over time. As an
example, age-related dementia is an example of a process with dire consequences for the inflicted
individuals and their family, but previously dementia was viewed as a normal phenomenon of ageing and
was not classified as a disease until 1906 [1].
Development of diagnostic technologies may also change what we classify as disease [2]. “Asthma” has
been described for centuries, the term thought to have originated from an ancient Greek word meaning
“panting” [3]. Therefore, the term “asthma” was used to describe all causes of breathlessness. With the
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development of diagnostic tests that could measure airway calibre, the term was narrowed to the process
that causes reversible bronchial constriction. Further development in definitions of bronchial inflammation
allowed us to refine and differentiate between different phenotypes of asthma. Thus, improvements in
diagnostic technology allow us to define “new” diseases and refine definitions of old ones.
The invention of the stethoscope by Laennec enabled him to describe the clinical features of bronchiectasis
for the first time and correlate with anatomical findings [4]. However, bronchiectasis was not frequently
acknowledged until the last two decades when it was appreciated that there was a greater prevalence of
bronchiectasis and consequently greater attention and research [5, 6]. High-resolution computed
tomography (HRCT) scanning allowed detection of bronchiectasis in people with symptoms that may have
been previously diagnosed as other diseases based on clinical features (e.g. asthma or chronic bronchitis).
Recent advances in phenotyping patients with bronchiectasis (e.g. biomarkers or genetics) may further
change the way we classify bronchiectasis.
In this review we will attempt to outline the arguments in favour and against labelling bronchiectasis as a
disease, looking at pathogenesis, aetiology, clinical features, patterns of inflammation and infection and
efficacy of treatment modalities. Lastly, we will focus on implications of the different approaches to
labelling bronchiectasis as a disease or otherwise.
Thesis: bronchiectasis is a disease
Bronchiectasis fulfils the dictionary definition of a disease. It is unquestionably the result of impaired
function of the airways and is characterised by distinguishing signs (i.e. radiographic features) [7, 8].
Although there are a number of aetiologies or associated conditions, a common pathophysiological
mechanism has been suggested, in which impaired mucociliary clearance and retention of airway phlegm,
consequent bacterial infection and inflammation contribute to a destructive process, leading to one
another and propelling bronchiectasis [9, 10].
A central feature of most cases of bronchiectasis is airway inflammation. GAGA et al. [11] found
increased inflammatory infiltrates in bronchial biopsies performed in patients with bronchiectasis
compared with healthy controls. Studies have further characterised inflammatory cells to include
lymphocytes (predominantly CD4 positive, with a smaller proportion of CD8 positive), abundant
neutrophilic infiltrate and increased presence of interleukin (IL)-8 [11–15]. Elevated neutrophil count has
been strongly correlated with impaired lung function, bronchiectasis severity and disease duration [11].
Neutrophil elastase, a serine protease produced by neutrophils and excreted in response to
infectious stimuli [16], has been found to increase in quantity during exacerbations of airways disease
and decrease after treatment of the exacerbation and with resolution of symptoms. In bronchiectasis
due to cystic fibrosis (CF), neutrophil elastase level was significantly correlated with the rate of lung
function decline [17]. In different research settings, neutrophil elastase has been proven to contribute
to disease severity being associated with an elevated risk of exacerbations, lung function decline and
mortality [18].
Another common finding in bronchiectasis is persistent infection of the airways by bacterial pathogens,
most notably Pseudomonas aeruginosa, Haemophilus influenza, Staphylococcus aureus and
non-tuberculous mycobacteria (NTM) as well as fungi [13, 19–22]. Infection with P. aeruginosa is
associated with worse outcomes including more frequent exacerbations, worse quality of life and elevated
mortality [22–25]. Inflammation is increased in people chronically infected with P. aeruginosa and
decreased in response to antimicrobial treatment, both short- and long-term [26].
We approach disease as a process that is responsive to therapy targeted towards the pathogenesis or
its downstream consequences. Recommended therapies for people with bronchiectasis primarily target
the consequences of bronchiectasis, such as airway obstruction and infection [27–29], but not all
therapies have equally established evidence of efficacy, nor will all patients benefit from all of these
therapies. Airway clearance techniques have been shown to improve mucus expectoration [30–34],
measures of airway inflammation [35], lung function [32], quality of life [30, 31, 35] and also to
reduce pulmonary exacerbations [30]. Antimicrobial treatment for acute exacerbations is
recommended [27–29] with evidence from small studies showing benefit in symptoms (sputum
volume and purulence, cough, dyspnoea) [36, 37], lung function [38] and inflammation [26, 36, 37].
Long-term antimicrobial treatment with macrolide antibiotics was found to decrease pulmonary
exacerbations and symptoms [39–41]. Studies of long-term inhaled antimicrobials have not shown
consistent results but there are reports of success in reduction of exacerbations [42–45]. Incorporating
the various aspects of bronchiectasis care into clinical practice results in improved clinical outcomes;
it has been shown that in patients under care at bronchiectasis centres, exacerbation frequency is
reduced over time [46].
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Antithesis: bronchiectasis is not a disease
Fundamentally, the word bronchiectasis means dilation of the bronchi; as such it describes an anatomical
abnormality. There are few other examples of anatomical, pathological or radiological terms which are also
used to describe diseases. This is because most such abnormalities usually can be caused by multiple
diseases or pathological processes. One example in the respiratory field of an anatomical abnormality also
used to describe a disease is pulmonary fibrosis. This term might be said to meet the criteria set out in
the introduction for diseases, since it has a defined pathophysiology and set of associated symptoms.
Nevertheless, we know clearly that pulmonary fibrosis caused by hypersensitivity pneumonitis is a very
different disease with a different treatment to usual interstitial pneumonia or sarcoidosis. Thus, pulmonary
fibrosis is a common anatomical phenomenon derived from a number of possible pathologies. It may not
always be possible to determine the initiating process (e.g. drug induced or hypersensitivity) solely on the
basis of the radiological morphology, but it is nonetheless important in order to treat correctly.
Similar to pulmonary fibrosis, typical symptoms of bronchiectasis are not exclusive: productive cough may
also occur in COPD (chronic bronchitis) without bronchiectasis, and dry cough (which is classically
described in pulmonary fibrosis) may be the main complaint in up to 27% of people with bronchiectasis [47].
Auscultatory findings of wheeze and rales are likewise far from specific. Physiologically, bronchiectasis is
classically characterised by obstructive air flow limitation. However, in a prospective multicentre study of
187 patients with bronchiectasis, only 41% had obstruction on spirometry, while 58% had a normal
spirogram [48]. Another study of 277 patients found an obstructive pattern in 43%, and 28.7% had a
restrictive or mixed pattern [49].
Radiological bronchiectasis is not specific or sensitive
The diagnosis of bronchiectasis is based upon the demonstration of airway dilatation on imaging.
However, defining this feature as the hallmark of bronchiectasis is problematic for several reasons. First,
radiological bronchiectasis is evident in other airway diseases. In asthma, the prevalence of bronchiectasis
is highly variable (more prevalent in severe cases) and ranges between 25 and 68% [50–55]. Likewise, there
are several studies performing HRCT chest scans that have found a prevalence of bronchiectasis >57% in
patients with COPD [50, 56–64].
One of the criteria for the diagnosis of bronchiectasis on HRCT chest scan is that the ratio of the
bronchus to an accompanying blood vessel is >1. However, chest CT scans in elderly people without
pulmonary symptoms have found increased bronchial diameter and an increase in bronchial wall thickness
in 40–60% of healthy elderly subjects [65–68]. Similar findings have been described in people with
rheumatoid arthritis (RA) with no pulmonary symptoms [69]. Therefore, mild radiological airway
dilatation, or cylindrical bronchiectasis, may be typical of normal ageing and be clinically unimportant.
Radiological features of bronchiectasis are not specific to clinical features of bronchiectasis. As an example,
bronchiectasis can be a feature of idiopathic pulmonary fibrosis (IPF), which behaves differently from
other cases of bronchiectasis as it is not typically associated with neutrophilic inflammation and is
uniformly excluded from the clinical definition of bronchiectasis in clinical practice and in registries [70, 71]
and clinical trials.
The finding of airway dilatation on HRCT may not be sensitive for the detection of early airway disease
that may eventually lead to overt bronchiectasis. In CF, it has been demonstrated that early structural
airway changes are dependent on the scanning protocol, and expiratory CT chest scans may result in a low
sensitivity for detection of airway abnormalities [72]. Likewise, in children, protracted bacterial bronchitis
(PBB) [73] and chronic suppurative lung disease (CSLD) [74] are clinically similar to bronchiectasis
(e.g. persistent symptoms, airway neutrophilia and chronic bacterial airway infection) without evidence of
bronchiectasis on imaging [75]. There is also evidence of “chronic wet cough” in adults without
bronchiectasis [76], which is hypothesised to be the adult equivalent of PBB/CSLD [77]. It may be
hypothesised that these two entities represent early stages of bronchiectasis, which may be reversible with
treatment [78].
In accordance with the entities of PBB and CSLD, there is no threshold for defining the minimal changes
on chest HRCT that are compatible with the definition of bronchiectasis. Likewise, treatment
recommendations do not change according to the extent of radiological involvement [27, 28, 79], and it is
not recommended to monitor changes in the extent of bronchiectasis on follow-up chest CT scans. Finally,
although radiological bronchiectasis is required to make the diagnosis, there is a poor correlation between
severity measures of bronchiectasis (e.g. symptoms, exacerbations and mortality) and the extent of
bronchiectasis on chest HRCT [24, 25]. In conclusion, typical HRCT chest findings are a prerequisite to
the diagnosis of bronchiectasis but are neither specific, sensitive, related to disease progression and
prognosis, nor to treatment recommendations. These data suggest that bronchial dilatation may be a
https://doi.org/10.1183/16000617.0051-2019 3
BRONCHIECTASIS | M. SHTEINBERG ET AL.
consequence of the underlying disease rather than being the disease itself, and may be prevented with
early treatment directed at the underlying disease as has been suggested in PBB/CSLD.
Bronchiectasis is heterogeneous and comprised of many different clinical entities
Bronchiectasis has many phenotypes that are distinct from each other [10]. Some of these phenotypes are
considered aetiologies (e.g. bronchiectasis associated with inflammatory bowel disease or with COPD)
while others are a description of distinctive clinical features (e.g. “dry bronchiectasis”) [47]. One of the
best studied but not the most common, is the phenotype of CF-associated bronchiectasis. CF is thought of
as a clinical syndrome of single gene disorder resulting in multiorgan involvement, with bronchiectasis as
the pulmonary manifestation. Coordinated centre-based CF care developed early on and separately from
that of bronchiectasis, and it is probably for historic reasons that CF is excluded from bronchiectasis
registries, clinical trials and guidelines [27, 80]. However, in recent years it has been increasingly
acknowledged that cystic fibrosis transmembrane regulator (CFTR) dysfunction is increasingly common
among people with bronchiectasis [81–86]: There is increased frequency of CF-causing mutations [81, 82]
and other CFTR variants [84, 86] than the frequency in the general population, as well as physiological
abnormalities that are related to CFTR deficiency in people with bronchiectasis [86, 87]. It is therefore
more useful to acknowledge that CFTR dysfunction is contributing to many people with bronchiectasis,
rather than to make the simple distinction of CF and non-CF bronchiectasis.
Similar to CF, other phenotypes of bronchiectasis exist that have distinct aetiology, clinical features and
therapeutic modalities. Perhaps the best example is primary ciliary dyskinesia (PCD). Like CF, PCD has a
distinct genetic aetiology, albeit more complex and not always identified [88]. Like CF, PCD shares airway
pathology with bronchiectasis but has distinct clinical features and extrapulmonary involvement (i.e.
middle ear infections, situs abnormalities, sperm dysmotility in males) [89]. Ongoing clinical trials (e.g.
inhibition of epithelial sodium channel, ClinicalTrials.gov Identifier: NCT02871778) test therapeutic
modalities in people with PCD and may lead to the first registered therapy for this indication. However,
PCD is currently considered as one of the aetiologies of bronchiectasis and people with
PCD-bronchiectasis are included in bronchiectasis registries and some clinical trials [90]. The convention
that CF-bronchiectasis is considered a different entity from bronchiectasis, while PCD-bronchiectasis is
not, is therefore methodologically inconsistent. For this reason, use of the term “non-CF bronchiectasis” is
now discouraged [91].
Other examples of bronchiectasis with distinct clinical features and specific treatment modalities also exist.
These are immune deficiencies, genetic and acquired (haematological malignancies), that may be treated
with immunoglobulin replacement therapy, autoimmune-related (such as RA and inflammatory bowel
disease (IBD) and allergic bronchopulmonary aspergillosis (ABPA), for which treatment with systemic
corticosteroids and anti-IgE antibodies are indicated. Asthma, COPD and chronic rhinosinusitis (CRS)
that are frequently causes and/or associated with bronchiectasis [50], have distinct treatment modalities, as
summarised in table 1.
Airway inflammation in bronchiectasis may also not be uniform. In the study by DENTE et al. [15] most
patients with bronchiectasis had elevated sputum neutrophils. However, 20% of patients had more than
3% eosinophils in sputum, with total sputum eosinophil count ranging from 0 to 70%. A subgroup of
eosinophilic predominant inflammation was also found in 17.5% of 40 patients in another study [92].
Similarly, in a previous single-centre study of people with bronchiectasis, presence of CRS was associated
with elevated peripheral blood eosinophils and IgE [93]. It may be that some people with bronchiectasis
have a type 2 inflammation, perhaps associated with asthma, CRS and ABPA, while the majority of people
with bronchiectasis have a neutrophilic inflammation. These differences may be important in developing
treatments that target inflammation in bronchiectasis.
Chronic infection is common in bronchiectasis, with P. aeruginosa being the most common organism
isolated [22, 47, 71]. However, presence of chronic infection is not uniform and ranges from 16% to 50%
in different series. While infection with P. aeruginosa is associated with worse outcomes [24, 25], The
impact of P. aeruginosa is also heterogeneous in relation to exacerbation frequency [22]. It is hypothesised
that the immune response to infection may impact on disease severity [94, 95].
Response to therapeutic interventions is not uniform and not specific
While there are recommended treatments for patients with bronchiectasis, based on published evidence,
these treatments are not uniformly successful in all patients with bronchiectasis. The best examples may be
treatments that were first indicated for CF, such as rhDNase [96] and inhaled tobramycin [97] which, in
bronchiectasis, did not result in successful outcomes. However, in some of the clinical trials, there was
evidence of benefit in some patients, with no success in identifying subgroups of patients in whom efficacy
is clear. One example is the efficacy of inhaled corticosteroids (ICS) in people with bronchiectasis.
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Single-centre studies demonstrated significant reductions in sputum production and improvement in
symptoms in patients with bronchiectasis [98, 99]. However, later studies did not show a similar benefit
although cough was significantly improved [100]. Currently, treatment with ICS is not recommended in
people with bronchiectasis, unless indicated for concomitant asthma or COPD [27]. It remains to be seen
whether future studies will be successful in defining subgroups of patients, perhaps according to patterns
of inflammation, which will be responsive to previously tested modalities, such as ICS, inhaled antibiotics
and rhDNase.
Therapeutic modalities with established efficacy in bronchiectasis are also far from specific and beneficial
in other airway diseases. Macrolides have proven efficacy in reducing exacerbations in CF [101], but also
in diffuse panbronchiolitis [102, 103], bronchiolitis obliterans in lung transplant recipients [104–106],
COPD [107–109], CRS [110] and, recently, asthma [111]. Airway clearance and inhaled mucolytic agents,
such as hypertonic saline, are the first-line treatment for CF [112]. Rehabilitation has established benefits
in COPD care [113], only later to be utilised in bronchiectasis.
Is bronchiectasis a “treatable trait”?
The concept of “treatable traits” in airway diseases was recently introduced [114]. It was suggested that, in
the age of precision medicine, a pragmatic, therapy-focused approach to airway disorders would be more
successful in treatment than classifying diseases and treating accordingly. Focusing on asthma and COPD,
classifying people into “diseases” may lead to suboptimal management because diseases with different
TABLE 1 “Treatable traits” of bronchiectasis
Trait Main diseases that
share the trait
Clinical features
Laboratory/physiological features
Targeted treatment
Chronic infection Protracted bacterial
bronchitis
Chronic wet cough Growth of pathogens in respiratory
secretions
Antimicrobials
Chronic bronchitis
(COPD)
Ciliary dyskinesia PCD Young age of symptom onset,
chronic otitis media, situs
abnormalities, male infertility
(asthenospermia), sinusitis
Low nasal NO, electron
microscopic abnormalities,
abnormal ciliary beating pattern
Inhaled saline, airway
clearance, ongoing trial of
ENaC inhibition
Secondary ciliary
dyskinesia#
CFTR dysfunction/
deficiency
CF Young age of symptom onset,
pancreatitis, malnutrition, bowel
obstruction, male infertility
(azoospermia), sinusitis
Elevated sweat chloride,
characteristic electrophysiological
abnormalities, CFTR mutations on
two alleles
CFTR modulators
CFTR-related
disorder
Secondary CFTR
dysfunction#
Immune deficiency Primary immune
deficiencies
Young age of symptom onset,
infection in extrapulmonary
sites
Immunoglobulin deficiencies,
impaired tests of immune function
IVIG
Secondary immune
deficiencies
Haematological malignancies
Systemic
inflammation
Rheumatoid arthritis Symmetric arthritis, morning
stiffness
Rheumatoid factor DMARDs, CS, anti-TNF-α
IBD Bloody diarrhoea, weight loss,
GI ulceration
Endoscopic appearance and
histology
Aminosalicylates, CS,
anti-TNF-α
Eosinophilic
inflammation
Asthma Seasonality Airway reversibility ICS, bronchodilators,
anti-IgE, anti-IL-5CRS Chronic nasal discharge, loss of
smell, facial pain
Sinus inflammation on endoscopy,
sinus CT
ABPA Wheeze, mucus plugs Elevated IgE, Aspergillus spp.
sensitisation
Gastro-oesophageal
reflux
GORD Symptoms of heartburn and
reflux
Endoscopic, motility and imaging
studies
Behavioural measures,
proton-pump inhibitors,
surgery
Examples of features of bronchiectasis that define a subgroup of patients. These may be viewed as “treatable traits” and some are shared with
other disease entities. CFTR: cystic fibrosis transmembrane regulator; PCD: primary ciliary dyskinesia; NO: nitric oxide; ENaC: epithelial
sodium channel; CF: cystic fibrosis; IVIG: intravenous immunoglobulins; DMARDs: disease modifying antirheumatic drugs; CS: corticosteroids;
TNF: tumour necrosis factor; IBD: inflammatory bowel disease; GI: gastrointestinal; ICS: inhaled corticosteroids; Ig: immunoglobulin; IL:
interleukin; CRS: chronic rhinosinusitis; CT: computed tomography; ABPA: allergic bronchopulmonary aspergillosis; GORD: gastro-
oesophageal reflux disorder. #: may be induced by smoking.
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endotypes require different therapeutic strategies. The classical approach limits our investigation of the
causes of morbidity of people whose symptoms do not meet the definition of one airway disease. This may
result in limited development of drugs that target one endotype and not another. Lastly, this approach
may also limit the generalisability of clinical trials, because many patients with a “disease” targeted in
clinical trials may have features of another “disease” and therefore are excluded from those trials, obvious
examples being the exclusion of people with airway reversibility from COPD trials and smokers from
asthma trials. The list of traits of airway diseases that was included in that paper contained, among others,
emphysema, eosinophilic inflammation and bronchiectasis.
Emphysema is considered to be a trait of people with the “classic” definition of COPD. Similar to
bronchiectasis, radiological emphysema may be asymptomatic or be associated with severe symptoms (e.g.
exercise intolerance). It is therefore not considered a disease by itself, but a clinical feature, or trait, of
people with COPD, especially smokers and, in the presence of α1-antitrypsin deficiency. Lung volume
reduction is a therapeutic option that targets emphysema, making the trait a treatable one [115].
Bronchiectasis was suggested to be one of the treatable traits of airways diseases [114]. However, the
diversity of bronchiectasis would make it very difficult to narrow into a treatable trait as the treatable
aspect suggests there is a narrow indicated treatment such as inhaled corticosteroids for the treatable trait
of eosinophilic inflammation. Rather, we suggest that bronchiectasis be viewed as a disease that is
heterogeneous and shares treatable traits with other diseases. Examples of treatable traits of bronchiectasis
may be airway infection (targeted by antimicrobials), failure of mucociliary clearance (treatable with airway
clearance and pharmacological adjuncts) and CFTR dysfunction (treatment with CFTR modulators).
Table 1 shows several examples of such treatable traits that are shared by subsets of people with
bronchiectasis and other airway and systemic diseases. Determining an aetiology or a treatable trait has
important implications for future care since identification of the underlying abnormality, which may be
inflammatory, ciliary or epithelial in origin, and early treatment may prevent the development of
bronchiectasis.
The treatable traits model is powerful specifically because it does not require a clinician to identify a
disease or to decide which disease is predominant in a specific circumstance. If your patient has airway
infection and frequent exacerbations, they may benefit from antimicrobial and anti-inflammatory
treatment with a macrolide regardless of whether the primary disease label is bronchiectasis, COPD or
asthma. Likewise, if the patient has exercise limitation and deconditioning, they are likely to benefit from
pulmonary rehabilitation regardless of the underlying disease label. Thus, moving from thinking of airway
diseases as labels and instead as complex systems composed of multiple traits may lead to more holistic
treatment.
Does it really matter?
AGUSTI et al. [114] suggest that the pulmonology community move away from “Oslerian” diagnoses
towards treatable traits definitions, but this approach does have implications to be considered. For health
authorities, labelling patients with distinct diagnoses allows planning and distributing health services, drug
and treatment registration, and more. For patients, naming their symptoms as a diagnosis may be
reassuring, apart from the hope of improving with treatment [116]. A repeated complaint from our
patients with bronchiectasis is that their condition was misdiagnosed and neglected for decades. Moving
away from labelling bronchiectasis as a disease may wipe away the important achievements of
bronchiectasis research and organisation of the past years. In asthma and COPD, heterogeneity and the
importance of phenotyping is increasingly recognised. However, the medical community has not moved
away from the definition of these diagnoses, and international guidelines on diagnosis and management
are still available and regularly updated [113, 117], while important advancement in “precision medicine”
directed towards specific phenotypes continue [118, 119]. The same should be the case for bronchiectasis:
maintaining the “disease” label while acknowledging its limitations, the heterogeneity of the disease and
the importance of identifying treatable traits to appropriately target new therapies.
Conclusion
Bronchiectasis is defined by distinguishing radiological and clinical features. The last decade has brought
significant advancement in the understanding of bronchiectasis and improvement of treatment. However,
difficulties in establishing therapeutic benefits have highlighted the great heterogeneity in bronchiectasis,
and raise the question of appropriateness of regarding bronchiectasis as a single clinical entity. It is our
opinion that, similarly to asthma and COPD, bronchiectasis should be defined as a disease, but that the
large heterogeneity and overlap in pathogenesis, clinical features and response to treatments be
acknowledged.
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